Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) is trading at unusually high volume Friday with 24.4 million shares changing hands. It is currently at 4.1 times its average daily volume and trading up $1.76 (+4.2%) at $44.16 as of 11:15 a.m. ET.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Eli Lilly and has a market cap of $49.72 billion and is part of the
industry. Shares are up 2% year to date as of the close of trading on Thursday.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has a P/E ratio of 11.7, below the average drugs industry P/E ratio of 11.8 and below the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Eli Lilly and as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. You can view the full
See all heavy volume stocks in our
or get investment ideas from our